

Real World Data Platforms and Disease Interception

Author: Martine Lewi, PhD, MBA, MSc, Scientific Director, Janssen R&D

Date: 24/05/2018



















"Unlocking Tomorrow's Cures"





AGENDA

- Changing trends in healthcare ecosystem
- Leveraging digital / RWD for Research & Development
- Future direction and value creation
- Key messages



CHANGING TRENDS IN HEALTHCARE ECOSYSTEM

Research & Development for "A world without disease"

Clinical manifestation

Onset of morbidity

No clinical manifestation

HEALTHY INCUBATION DISEASE

PREVENTION

Disease-specific approaches to warding off onset of disease initiation

INTERCEPTION

Arrest disease as it develops before clinical manifestations

CURE

Eliminate disease and reverse damage to restore full health

DISEASE ELIMINATION





Our perspective on clinical innovation and Digital

R&D in 2017

- > 400 trials
- > 30 countries
- > 16.000 sites
- > **116.000** participants



New opportunities

- digital biomarkers
- remote patient monitoring
- real-time access to EHR/RWD

Mission

Transform clinical development for patients, investigators and industry

Approach

Reduce cost of evidence acquisition and improve patient satisfaction

Deliverable

Clinical trial outcomes and new operational capabilities


Persistent challenges

Recruitment

- Access to patients (data)
- Bring the trial to the patient


Retention

- Improve patient experience
- Unobtrusive trials






Body Area Network





Our perspective on clinical innovation and RWD

Optimizing various aspect of R&D through data, insight & knowledge solutions, applying FAIR principles, harmonisation, analytics, machine learning to enable learning



IMI EMIF - http://www.emif.eu/

IMI/EHDEN-http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/imi2-2017-12-04.html (a) and (b) and (c) are also as a constant of the cons

IMI/EHR4CR - http://www.ehr4cr.eu/

eIT/EHR2EDC - https://www.eithealth.eu/ehr2edc

OHDSI - https://www.ohdsi.org/


Janssen Clinical Innovation / Patient Data for Research - http://www.janssen.com/clinical-trials/innovation



RWD defined ...


RWE is generated using data typically collected in **usual health care settings**. RWE is most commonly **generated using a range of non-interventional (observational) studies**, including:

- Primary data collections such as registries collecting prospective and/or retrospective data, or surveys collecting cross-sectional or retrospective information.
- Analyses of secondary data that includes (electronic) medical records, insurance claims
 data, and government databases which provide data typically used for retrospective
 analyses.






Federated data management ensures secure access to RWD from a variety of different EHR sources






Emerging integrated health regions in EU provide opportunities for data-driven research collaboration




EHR/RWD enables health learning systems and accelerates advancements in medical science

Based on specialty datasets (e.g. cohorts)



Based on "general" datasets (e.g. hospital data)



... enhancing the medical knowledge to improve prevention, interception and cure





The European Institute For Innovation Thr~ugh Health Data

A European think tank enabling learning systems based on EHR/RWD

Value to healthcare

Value to research

Value to patients and to society

Grow a Network of Excellence

Demonstrate benefits of using health data on a large scale:

- outcomes evidence to improve care
- faster and more efficient clinical research
- information for public health decisions

Promote and collaborate globally



Enriching knowledge and enhancing care through health data ... supporting the transitioning towards disease interception and prevention




European Health Data & Evidence Network (EHDEN) realizes a secure data sharing environment...

Aim is to link 100 million health records across EU via a common data model (OMOP), supporting research, the BD4BO IMI2 programme, and outcomes-based healthcare

- Advance skill base in EU via certified& qualified SMEs
- Harmonisation fund to support mapping to CDM

- Incorporation of outcome standards (e.g. ICHOM)
- Supporting evidence base in EU for outcomes-based research and medicine



- Building on prior and current (IMI) projects
- Accelerate platform and supporting research process
- Federated network of increasing number of Data Custodians and Sources
- Evaluation and incorporation of 'novel' data sources
- Utilisation of FAIR Principles

EHDEN will be an IMI consortium of 11 EFPIA partners and a public consortium of 11 partners, planned to commence October 2018



KEY MESSAGES

Unlocking Cures ... Towards a "World Without Disease"

- Patients are waiting for a new health model, which puts prevention and disease interception at the foreground, besides more targeted and personalized treatments.
- 2. Data and knowledge driven research collaboration are the engine to accomplishing this major shift in the health care ecosystem.
- 3. Europe has built a strong foundation in data and knowledge driven initiatives ... A strong vision, strategy and tactics aiming to achieve these patient-focused goals are in place ... strong policies can support these accomplishments.

Open the discussion on this topic with attending policy makers



THANK YOU!

Q&A



